Cointime

CASI Pharmaceuticals

company

About

CASI focus on building a pipeline through mutually beneficial business development transactions.

  • 101 - 250

Highlights

Total Funding Amount
$50M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$50M
Industries
Biotechnology,Medical,Pharmaceutical
Founded date
Jan 1, 1991
Number Of Employee
101 - 250
Operating Status
Active

CASI Pharmaceuticals, Inc. ("CASI", "we" or "us") is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. CASI is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. CASI is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market leveraging CASI's China-based regulatory and commercial competencies and its global drug development expertise.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$50M
CASI Pharmaceuticals has raised a total of $50M in funding over 2 rounds. Their latest funding was raised on Mar 20, 2018 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 20, 2018 Post-IPO Equity $50M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
CASI Pharmaceuticals is funded by 1 investors. ETP Fund are the most recent investors.
Investor Name Lead Investor Funding Round
ETP Fund — Post-IPO Equity
Cointime
เนื้อหา
บริษัท